Ironwood Capital

Ironwood Capital is a Connecticut-based private equity firm specializing in providing non-control growth capital to middle-market companies. The firm invests in the form of subordinated debt and preferred stock, typically ranging from $5 million to $20 million, to support business owners and financial sponsors in growth financings, full and partial recapitalizations, generational transitions, and buyouts. Over the past 16 years, Ironwood has invested more than $700 million in over 125 companies across various industries.

The firm's investment strategy focuses on partnering with management teams to drive growth and operational improvements. Ironwood has a particular interest in sectors such as business services, consumer products and services, life sciences and healthcare, manufacturing and industrial, and transportation and distribution. The firm has a history of investing in companies with annual revenues between $10 million and $200 million and EBITDA margins of approximately 10% or better.

Ironwood Capital has a track record of successful investments, including notable exits such as IsoPlexis, Modifi Bio, and Payveris. The firm's approach emphasizes clear alignment of interests, complete transparency, adherence to strategy, robust reporting, and active co-investment and cross-referral programs. These principles have contributed to Ironwood's longevity and success in the private equity industry.